Source: United States & Canada – South China Morning PostUS pharmaceutical firms Merck and Moderna announced on Wednesday encouraging results from a trial of their experimental vaccine against melanoma, potentially clearing the way for approval.
The vaccine, called intismeran autogene, showed “statistically significant and clinically meaningful improvements” for skin cancer patients when used with Merck’s Keytruda treatment, the companies said in a statement.
Unlike conventional vaccines, so-called therapeutic vaccines like intismeran treat rather…Read More